SRDX
$37.76
Surmodics
$.62
1.67%
SRDX
Earnings Whisper ®
N/A
3rd Quarter June 2020
Consensus:  ($0.04)
Revenue:  $18.31 Mil
Wednesday
Jul 29
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when SRDX reports earnings?
Beat
Meet
Miss

Where is SRDX's stock price going from here?
Up
Flat
Down
Stock chart of SRDX
Analysts
Summary of analysts' recommendations for SRDX
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics' Bravo drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics' revenue is generated by royalties earned from the sale of our customers' commercial products.
Peers
ImmunomedicsMyriad GeneticsQuidelCareDxMeridian Bioscience